WaveMan
WaveMan · Company
BIOE · Bio Essence Corp
> Search tickers & screens ⌘K
LIVE
← All companies

BIOE Bio Essence (BIOE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001723059
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about BIOE

Planned sales (Form 144), 90 days
$148.5K
1 notice

Bio Essence insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Bio Essence Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Yan Yin
Chief Executive Officer
SELL
2026-10-14 SECtraded 2024-10-30
143,845
$82.0K
+27.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (1 buy, 12 sales), the last on Oct 29, 2024.
  • The trade is 1.1% of the 13,396,000 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Chief Executive Officer Yan Yin sold about $82.0K of BIOE on Oct 30, 2024.
Yan Yin
Chief Executive Officer
SELL
2024-11-18 SECtraded 2024-10-29
40,000
$25.6K
+53.8%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (1 buy, 10 sales), the last on Oct 28, 2024.
  • The trade is 1561.8% of the 2,561 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Chief Executive Officer Yan Yin sold about $25.6K of BIOE on Oct 29, 2024.
Yan Yin
Chief Executive Officer
SELL
2026-10-14 SECtraded 2024-10-29
4,000
$2.6K
+27.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (1 buy, 10 sales), the last on Oct 28, 2024.
  • The trade is 0.0% of the 13,539,845 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Chief Executive Officer Yan Yin sold about $2.6K of BIOE on Oct 29, 2024.
Yan Yin
Chief Executive Officer
SELL
2026-10-14 SECtraded 2024-10-28
140,000
$347.5K
+27.3%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (1 buy, 9 sales), the last on Sep 30, 2024.
  • The trade is 1.0% of the 13,543,845 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Chief Executive Officer Yan Yin sold about $347.5K of BIOE on Oct 28, 2024.
Yan Yin
Chief Executive Officer
SELL
2024-10-10 SECtraded 2024-09-30
1,990
$4.7K
-86.5%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Sep 27, 2024.
  • The trade is 0.0% of the 13,683,845 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Chief Executive Officer Yan Yin sold about $4.7K of BIOE on Sep 30, 2024.
14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 9 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+485.8% year over year
more than 93% of Pharma & Biotech
Margin
47.2% net margin
more than 95% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Oct 14Chief Executive Officer Yan Yin sold $432.0K (3 trades, Oct 28, 2024 to Oct 30, 2024)
Oct 13Director and Chief Executive Officer YIN YAN filed to sell $148.5K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch BIOE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+508.7%12M
-26%+199%+424%+649%2025-102025-122026-022026-042026-062026-082026-10 2026-10-13 · YIN YAN filed to sell $148.5K
Form 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BIOE: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in BIOE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BIOE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
YIN YAN
Filed 2026-10-13
$148.5K
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows $148.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BIOE financials

Revenue growth
+485.8%
XBRL, annual
Net margin
47.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+52.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.02x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
18.93x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
+73.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
invested capital is zero or negative
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$22.6M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term debt only, 2026-06-30, minus cash 2025-09-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.9M$323.9K$551.5K$985.8K
Gross profit$1.4M$217.1K$277.4K$328.3K
Operating income$900.0K-$459.4K-$345.6K-$511.1K
Net income$896.2K-$1.3M-$971.9K-$809.7K
EPS (diluted)n/a-0.03-0.03-0.02
Operating cash flow$1.6M$623.9K-$1.0M-$703.2K
Cashn/a$1.4K$114$6.3K
Long-term debt$57.5K$56.5Kn/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

BIOE Stock Sonar score 3/7 axes

Find similar shapesCompare

BIOE ranks highest on risk and compliance (99th percentile) and growth (93rd), and lowest on financial health (84th), among Pharma & Biotech peers.

Financial health
84
Inputs
  • Debt to equity0.02x · 70 pct, sector of 352
  • Cash flow to debt18.93x · 98 pct, sector of 371
Growth
93
Inputs
  • Revenue growth, YoY+485.8% · 93 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
100
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; invested capital is zero or negative
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BIOE filings, in plain words

Are there planned insider sales of BIOE?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $148.5K of stock; the latest, by YIN YAN, was filed 2026-10-13.

Read the full summary

Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $148.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies